AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
New York, NY – November 12, 2025 – The U.S. stock market presented a landscape of diverging fortunes today, as the Dow Jones Industrial Average surged to new record highs, fueled by mounting optimism for an end to a protracted government shutdown, while the tech-heavy Nasdaq Composite experienced a notable decline.
The Dow Jones Industrial Average (DJIA) has surged to unprecedented levels, marking new all-time highs this week, even as the nation holds its breath for a pivotal vote in the U.S. House of Representatives. On Tuesday, November 11, 2025, the Dow closed at a record 47,927.96, continuing
The economic outlook for the U.S. Midwest has taken a concerning turn as the Chicago Federal Reserve's 7th District hiring expectations index reportedly plummeted to -40 in October 2025. This alarming figure represents the lowest reading for hiring expectations since the tumultuous year of 2020 and, excluding the pandemic
AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and the persistence of headwinds in the aesthetics segment. CEO Rob Michael acknowledged challenging economic conditions affecting discretionary spending and emphasized the company’s execution in core therapeutic areas.
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in turn, significantly bolstered the US Dollar, pushing it to multi-month highs against a basket of major currencies. The immediate implication for
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant announcement, made well in advance of the payment date, underscores the company's robust financial health and unwavering commitment to
